Kendra Wilkinson Shares GLP-1 Weight Loss Journey

Kendra Wilkinson is opening up about her weight loss. The former Girls Next Door star recently shared that she has dropped four dress sizes since starting a GLP-1 medication. She’s 40 now, and she says the change is easy to see. Her old jeans fit again.

Wilkinson hasn’t focused on the scale. Instead, she’s been tracking her progress by how her clothes fit. That’s a simple, relatable way to measure change, and it’s one many people use instead of obsessing over numbers.

So what exactly is a GLP-1 drug, and why has it become such a big deal? GLP-1 stands for glucagon-like peptide-1. It’s a hormone your body already makes. These medications essentially copy that hormone to help regulate appetite and blood sugar.

Here’s how it works in practice. The drug slows down how quickly food leaves your stomach. As a result, you feel full longer after eating. Over time, that can lead to eating less and, for many people, losing weight.

You’ve probably heard of some of these medications by now. Novo Nordisk markets semaglutide under the brand names Ozempic and Wegovy. Eli Lilly sells tirzepatide as Mounjaro. The FDA has approved all three drugs, though not for the same use.

The FDA approves Ozempic and Mounjaro specifically to manage type 2 diabetes. It approves Wegovy, on the other hand, for chronic weight management. That distinction matters, especially since so many people now use these drugs off-label just for weight loss.

And that’s exactly what’s happening more and more. Off-label use has surged in recent years. It’s raised real questions among doctors, insurers, and regulators about access, safety, and cost.

Wilkinson mentioned that she worked with a service that connects patients to licensed medical providers. This kind of telehealth model has become increasingly common. Patients complete a virtual consultation, and a provider prescribes the medication when it fits their health needs.

It sounds convenient, and often it is. But there’s a catch worth knowing about. The FDA has warned about counterfeit and compounded versions of these drugs circulating outside licensed pharmacies, and those products can carry serious risks.

That’s why medical supervision matters here. GLP-1 medications aren’t without side effects. Nausea and vomiting are common, especially early on, and more serious complications, while rare, can happen too.

Doctors typically screen patients before starting treatment. They’ll ask about personal and family medical history, including certain thyroid conditions that could make the medication unsafe for some people. People often skip this step when they buy these drugs without proper medical oversight, and that worries public health experts.

Wilkinson’s story fits into a larger pattern. More celebrities are talking openly about using GLP-1 drugs to manage obesity and excess weight. It’s helped normalize the conversation, though it’s worth remembering that one person’s experience doesn’t predict everyone else’s results.

Weight loss with these medications varies a lot. Dosage, consistency, diet, and overall health all play a role. What works well for one person, according to NIDDK weight management guidance, might look completely different for someone else, particularly given how widely obesity affects U.S. adults.

Coverage adds another layer of complexity. The Centers for Medicare and Medicaid Services has weighed proposals on whether it should cover these drugs when doctors prescribe them for obesity rather than diabetes, and that policy debate is still unfolding.

For now, Wilkinson seems happy with her progress. She’s sharing it openly, jeans and all. But as with any prescription medication, doctors recommend proper medical guidance rather than going it alone.